Gulf Pharmaceutical Industries 澳门尼斯人游亚洲官网 announces Q3 2022 results.

• 2022年实现持续的季度环比增长

•2022年第三季度来自AED 415的持续运营净销售额.7m

•2022年第三季度持续经营业务的EBITDA接近47迪拉姆.5m;

• 公司持续经营的年初至今EBITDA为131迪拉姆.7米的使

• Top line and bottom line results are better than the ambitious 2030 growth strategy expectations.

09年11月, 2022, Ras Al Khaimah (阿联酋): Gulf Pharmaceutical Industries PSC (澳门尼斯人游亚洲官网 or the Company), one of the largest pharmaceutical manufacturers in the Middle East and Africa, today reports its financial results for the third quarter ending 30 September 2022.

2022年第三季度, 澳门尼斯人游亚洲官网 demonstrated continued growth quarter on quarter and year over year  with AED 415.预计2022年第三季度净销量为700万辆，同比增长12%.从368迪拉姆上涨了9%.2021年第三季度将达到200万.

This increase is attributable to organic growth from 澳门尼斯人游亚洲官网’s segment operations, and reflects the Company’s increased focus on its core markets in the Middle East and North Africa, improved market access and the expansion of the company’s product portfolio with new launches.

The Company’s EBITDA from continuing operations increased quarter-on-quarter to AED 47.5米，与AED 44相比.2022年第二季度为200万美元.

公司年初至今EBITDA达131迪拉姆.700万美元，反映出标准化EBITDA同比有所改善.

Q3 EBITDA % of 网 sales reaches again double digit figure (11.4%)势头强劲, and confirming adherence of 澳门尼斯人游亚洲官网 towards the strategic outlook toward the future, as per the mid/long term strategic growth commitments defined in Q1 of 2022.

Underpinning the Company’s improved performance is the continued successful implementation of its two-year strategic turnaround plan, which has seen the Company divesting from non-core and loss-making activities and delivering efficiency improvements in its manufacturing operations.

Sheikh Saqer Bin Humaid Al Qasimi, 董事局主席, 澳门尼斯人游亚洲官网, said: “The first nine months of 2022 have seen the 澳门尼斯人游亚洲官网 executive team lay the strong foundations for continued, sustainable growth as aligned to our Strategic Objectives 2030. Our return to profitability in the second quarter and continued momentum is evidenced by our strong results for the third quarter. 澳门尼斯人游亚洲官网 has showcased that it has a robust strategy with a capable and agile leadership team. I am confident that the Company will meet its 2030 objectives and deliver shareholder value."

Dr. 埃及穆罕默德, 澳门尼斯人游亚洲官网的首席执行官, said: “澳门尼斯人游亚洲官网的旅程 throughout the first nine months of 2022 has demonstrated the continued potential of 澳门尼斯人游亚洲官网 and its offering. The strong third quarter results are testament to the strategic turnaround plan that we completed in early 2022, 并展示了澳门尼斯人游亚洲官网的持续价值潜力. 到2022年底, 澳门尼斯人游亚洲官网 remains on track to deliver on market guidance and we will continue to expand our geographic reach and introduce new products, with the ultimate ambition of providing sustainable value for patients, 股东, 和利益相关者.”

2022年初, 公司宣布了2030年增长战略, that aims to deliver sustainable growth and value to all stakeholders, 同时使澳门尼斯人游亚洲官网的收入增加了两倍.  The strategy is built around six core pillars; maximizing revenue from its current product portfolio, 新产品发布, 地理扩张, 策略性业务计划, 先进的特色产品计划, 无机增长计划.

年初至今, the company has launched 25 new products and remains committed on track to deliver its full year 2022 objectives including growth of market share in current operating territories, achieving sustained profitability and enhancing operational efficiencies.

该公司正在投资于内部研发&D to develop a robust and sustainable pipeline and plans to launch more than 86 new products in well-defined new therapeutic areas in the coming years.

• 结束- - -

关于澳门尼斯人游亚洲官网:

澳门尼斯人游亚洲官网 is one of the largest pharmaceutical manufacturers in the Middle East and Africa, 四十多年来, 公司一直在提供高质量的产品, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, 澳门尼斯人游亚洲官网雇佣了超过2名员工,400 people and distributes pharmaceutical products to more than 50 countries across the globe.

澳门尼斯人游亚洲官网’s business is centered on two core business units – 澳门尼斯人游亚洲官网 Diabetes Solutions and General Medicine Division, 哪些主要的治疗领域包括胃肠病学, 疼痛管理, 伤口护理, 抗生素和心脏代谢. 澳门尼斯人游亚洲官网 has 12 internationally accredited manufacturing facilities in the emirate of Ras Al Khaimah, 阿联酋. In 2012, 澳门尼斯人游亚洲官网 became one of the largest producers of Insulin with its 阿联酋-based biotechnology production unit. 了解更多信息,请访问 http://www.julphar.网

媒体联络: 《威尼斯澳门人亚洲官网》，澳门尼斯人游亚洲官网.

邮件:XXX
M: +971505777883